Mitomycin Injection Solution Recalled Due to Lack of Sterility Assurance
Mitomycin Injection Solution manufactured by Northern VA Compounders PLLC is being recalled because sterility cannot be assured. Patients receiving this product should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a sterile injectable drug where sterility cannot be assured, representing a risk-of-harm scenario. No illnesses or injuries have been reported, placing this in the High category per the rubric.
Plain-English summary
The U.S. Food and Drug Administration (FDA) is recalling Mitomycin Injection Solution, 4 mg/mL packaged in 10 mL multiple-dose vials, manufactured by Northern VA Compounders PLLC. The affected lots are Lot 12062022@7 (expiration 1/20/2023) and Lot 12072022@32 (expiration 1/22/2023).
The manufacturer has determined that sterility cannot be assured for these vials. As an injectable drug, sterility is a critical safety requirement.
The product was distributed nationwide in the United States. If you received this product, contact your healthcare provider or pharmacist immediately. Do not use the recalled vials.
The recalled product
- Product
- Mitomycin Injection Solution, 4mg/ml, packaged in a 10 mL Multiple-Dose vial, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Manufacturer
- Northern VA Compounders PLLC
- Category
- Drug — Chemotherapy
- Hazard
- sterility-assurance
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot#: 12062022@7
- Exp 1/20/2023
- 12072022@32
- Exp 1/22/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27